Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscleinvasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu ′erin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.

Necchi A., Roumiguie M., Esen A. A., Lebret T., De Wit R., Shore N. D., ...More

Genitourinary Cancers Symposium, ELECTR NETWORK, 16 - 18 February 2023, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Country: ELECTR NETWORK
• Dokuz Eylül University Affiliated: Yes